Fig. 1From: The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural modelsStudy design. COPD, chronic obstructive pulmonary disease; FDA, Food and Drug Administration; ID, identification; UMEC/VI, umeclidinium/vilanterolBack to article page